Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products
In March 2022, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products.” This document provides detailed recommendations for industry and academic sponsors involved in the development of CAR T cell therapies, aiming to streamline the development process and ensure the […]